Mobile

Six week, double-blind, placebo controlled Phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-005501-28

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

1. To establish efficacy of oral ziprasidone compared to placebo in the treatment of adolescent subjects with schizophrenia, as measured by the change from baseline to Week 6 in Brief Psychiatric Rating Scale - Anchored (BPRS-A) total score. 2. To evaluate the safety and tolerability of oral ziprasidone over 6 weeks in the treatment of adolescent subjects with schizophrenia.

Critère d'inclusion

  • Schizophrenia

Liens